

SCOPE	IDENTIFYING IMPAIRMENT		
<p>Does NOT apply to impairment of:</p> <ul style="list-style-type: none"> Inventory (see IAS 2); Assets from construction contracts (IAS 11); Deferred tax assets (IAS 12); Assets from employee benefits (IAS 19); Financial assets; other than subsidiaries, associates and joint ventures; Investment property measured at FV (IAS 40); Biological assets measured at FV less disposal cost (IAS 41); Assets from insurance contracts (IFRS 4); Non-current assets that are held-for-sale or discontinued operations (IFRS 5). 	<p>Assess all assets for indication of impairment at the end of each reporting period. If <i>indicators</i> exists → estimate <i>recoverable amount</i> and test for impairment.</p>		
	<p>Minimum impairment indicators to consider include:</p>		
	<p>External sources of info:</p> <ul style="list-style-type: none"> ↓ in asset's value significantly more than expected for passage of time/normal use. Significant & adverse technological, market, economic or legal environment changes. ↑ in market interest rates/returns (that are likely to cause a material ↓ in recoverable amount). Entity's net assets > market capitalization. 	<p>Internal sources of info:</p> <ul style="list-style-type: none"> Evident obsolescence/physical damage Significant & adverse changes in (expected) use of asset (e.g., idle assets, discontinuation/restructuring plans, change in disposal plans/useful life finite rather than indefinite). Evidence that economic performance of asset is/will be worse than expected. 	<p>Dividend from subsidiaries/associates/joint venture recognized and evidence that:</p> <ul style="list-style-type: none"> Carrying amount of investment in separate F/S > carrying amount of investee's net assets in consolidated F/S (including associated goodwill); or Dividend recognized > total comprehensive income of the subsidiary, associate or joint venture in period declared.
	<p>May also indicate need to review/adjust useful life, depreciation or residual value.</p>		
<p>MEASURING RECOVERABLE AMOUNT</p>			
<p>Higher of:</p>			
<p>Fair value (FV) less disposal costs: Price received to sell asset/paid to transfer liability in an orderly transaction between market participants @ measurement date, less incremental costs directly attributable to disposal (excluding finance costs and income tax expense).</p> <ul style="list-style-type: none"> Examples of disposal costs: legal costs, taxes, removal costs - NOT termination benefits. 		<p>Value in use: PV of future cash flows expected from asset/CGU (see IAS 36 for detail).</p> <ul style="list-style-type: none"> Exclude financing, income taxes and future restructuring/improvements to which not committed. Utilize pre-tax discount rate, reflecting specific risks of asset/CGU. 	
<p>Determine for individual asset UNLESS asset does not generate cash flows that are largely independent of those from other assets (e.g., corporate assets) → estimate for CGU to which asset belongs (not applicable if <i>value in use</i> close to <i>FV less disposal costs</i> OR <i>FV less disposal costs</i> > carrying amount).</p> <ul style="list-style-type: none"> If <i>FV less disposal costs</i> NOT possible to determine → use <i>value in use</i>. <p>Cash generating unit (CGU): Smallest identifiable group of assets that generates cash inflows that are largely independent from other assets/groups of assets.</p> <ul style="list-style-type: none"> Identify as separate CGU if active market exists for the output, even if some/all used internally. Internal transfer pricing → use management's best estimate of future price(s) that could be achieved in arm's length transaction when estimating cash flows. 			
<p>RECOGNIZING AND MEASURING IMPAIRMENT LOSSES</p>			
<p>Regardless of whether indicators exist, annually test:</p>			
<p>Intangibles with indefinite useful life/not yet available for use</p> <ul style="list-style-type: none"> Test at same time annually. First test performed before the end of the annual period in which it was initially recognized. 		<p>Goodwill acquired in business combination</p> <ul style="list-style-type: none"> Allocate goodwill to CGUs or groups of CGUs that are expected to benefit from the synergies of the combination (regardless of whether assets/liabilities of the acquiree are assigned to those CGUs). Allocation unit based on lowest level within the entity at which the goodwill is monitored for internal management purposes AND is =< an operating segment before aggregation. Test at same time annually by testing the CGU to which it has been allocated. First test performed at end of annual period in which business combination affected. Test after other assets/CGUs if tested at the same time. Gross up goodwill where NCI measured at % interest in net identifiable assets (rather than at FV) - refer to IAS 36.C4 for guidance. 	
<p>Recoverable amount < carrying amount → reduce carrying amount to recoverable amount</p> <ul style="list-style-type: none"> Recognize impairment loss in P/L UNLESS revalued asset. If revalued asset → treat as revaluation decrease to extent that impairment loss not greater than revaluation surplus → excess in P/L. <p>Impairment loss on CGUs:</p> <ul style="list-style-type: none"> First, reduce goodwill allocated to CGU; then, allocate to assets in CGU on pro-rata basis (treat as impairment loss for individual assets). Do NOT reduce carrying amount below higher of: <i>FV less disposal cost/value in use</i> (if measurable/determinable) and zero → allocate excess pro-rata to other assets in CGU. 			
<p>REVERSING IMPAIRMENT</p>			
<p>At end of reporting period, assess for indication that impairment from prior periods has decreased/no longer exists – impairment of goodwill is NOT reversed!!</p> <ul style="list-style-type: none"> The indicators of impairment reversal mainly mirror the <i>indicators of impairment</i>. If <i>indicators</i> exist → estimate <i>recoverable amount</i>. If <i>recoverable amount</i> > carrying amount AND estimates used to determine the asset's <i>recoverable amount</i> since the last impairment loss has changed (i.e., increase NOT due to passage of time) → increase carrying amount to <i>recoverable amount</i> BUT not higher than original carrying amount (net of depreciation/amortization) which would have otherwise resulted had no impairment loss been recognized. Recognize reversal in P/L UNLESS revalued asset. If revalued asset → recognize reversal in P/L to extent that impairment loss was recognized in P/L instead of comprehensive income → treat excess reversal as a revaluation increase in accordance with other IFRS. <p>Reversal on CGUs:</p> <ul style="list-style-type: none"> Allocate reversal to assets in CGUs (excluding goodwill) on pro-rata basis → allocate excess (above old carrying amount net of amortization) pro-rata to other assets in CGU. 			

This communication contains a general overview of the topic and is current as of March 31, 2017. The application of the principles addressed will depend upon the particular facts and circumstances of each individual case. Accordingly, this publication is not a substitute for professional advice and we recommend that any decisions you take about the application or not of any of the information presented be made in consultation with a qualified professional, who can address any variance that may be required to reflect your circumstances. Please contact your local MNP representative for customized assistance with the application of this material. MNP LLP accepts no responsibility or liability for any loss related to any person's use of or reliance upon this material. © MNP LLP 2017. All rights reserved.